SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
No hay miniatura disponible
Fecha
2021
Autores
D'Marco, Luis
Morillo, Valery
Gorriz, José Luis
Suarez, María K.
Nava, Manuel
Ortega, Ángel
Parra, Heliana
Villasmil, Nelson
Rojas-Quintero, Joselyn
Bermúdez, Valmore
Título de la revista
ISSN de la revista
Título del volumen
Editor
Hindawi
Resumen
Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in proinflammatory cytokines and with an improvement in the inflammatory profile in chronic endocrine-metabolic diseases. Hence, these drugs have been positioned as first-line therapy in the management of diabetes and its multiple comorbidities, such as obesity, which has been associated with persistent inflammatory states that induce dysfunction of the adipose tissue. Moreover, other frequent comorbidities in long-standing diabetic patients are chronic complications such as diabetic kidney disease, whose progression can be slowed by SGLT2i and/or GLP-1RA. The neuroendocrine and immunometabolism mechanisms underlying adipose tissue inflammation in individuals with diabetes and cardiometabolic and renal diseases are complex and not fully understood. Summary. This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise.
Descripción
Palabras clave
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide 1 receptor agonists (GLP-1RA), glycemic control, antihyperglycemic, Management of diabetes, Patients obesity and cardiorenal compromise
Citación
Luis D'Marco, Valery Morillo, José Luis Gorriz, María K. Suarez, Manuel Nava, Ángel Ortega, Heliana Parra, Nelson Villasmil, Joselyn Rojas-Quintero, Valmore Bermúdez, "SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence", Journal of Diabetes Research, vol. 2021, Article ID 9032378, 17 pages, 2021. https://doi.org/10.1155/2021/9032378